fbpx

Exactech Q2 Revenue Up 8% to $66.1 Million. Net Income up 20% to $4.4 Million. Diluted EPS $0.31 vs. $0.26.

Gainesville, Fla. (Aug. 1, 2016) – Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, today announced revenue of $66.1 million for the second quarter of 2016, an 8% increase from $61.5 million in the second quarter of 2015. On a constant currency basis, revenue was up 7%. Net income increased 20% to $4.4 million, or $0.31 per diluted share, compared to $3.7 million, or $0.26 per diluted share, in the same quarter a year ago.

Second Quarter Segment Performance

The following are company revenue results, as well as adjusted revenue comparisons on a constant currency basis:

  • Extremity implant revenue increased 18% to $24.2 million, an 18% constant currency increase
  • Knee implant revenue increased 1% to $19.2 million, flat on constant currency
  • Hip implant revenue increased 13% to $12.4 million, a 12% constant currency increase
  • Biologic and Spine revenue decreased 7% to $5.4 million, an 8% constant currency decrease
  • Other revenue decreased 6% to $4.9 million, an 8% constant currency decrease

Six Months Highlights and Segment Performance

For the first six months of 2016, revenue was $131.4 million, an increase of 7% over $122.9 million for the comparable period last year. On a constant currency basis, revenue for the first half of 2016 was also up 7%. Net income for the first six months of 2016 increased 13% to $8.8 million, or $0.62 per diluted share compared to $7.8 million, or $0.55 per diluted share, for the first six months of 2015. First six month product revenues were as follows:

  • Extremity implant revenue increased 16% to $48.4 million, a 17% constant currency increase
  • Knee implant revenue increased 3% to $38.6 million, a 3% constant currency increase
  • Hip implant revenue increased 8% to $23.7 million, an 8% constant currency increase
  • Biologic and Spine revenue decreased 2% to $10.8 million, a 1% constant currency decrease
  • Other revenue decreased 10% to $9.9 million, a 10% constant currency decrease

Management Comment

Exactech CEO and President David Petty said, “We are pleased with our first half performance, which was led by our shoulder and hip implant revenues as demand continued to be strong. Revenues from shoulder implants, our largest operating segment, were up 16% in the first six months and up 18% in the second quarter, which we believe indicate good momentum going forward. Similarly, hip sales were up 8% for the first six months with a strong 13% gain in the second quarter, continuing to reflect the success of our revision hip stem release.  Knee revenue was up 3% for the first six months and rose 1% in the quarter. Our strengthened sales team is performing well, and we are continuing to attract new customers. We are continuing to invest aggressively in R&D focused on both new products and innovative production capabilities.

“Worldwide sales increased 7% to $131.4 million for the first half of 2016.  U.S. sales were up 8% to $89.2 million compared with $82.5 million in the first six months a year ago. International sales increased 5% to $42.2 million. U.S. sales for the second quarter of 2016 were up 8% to $44.6 million compared with $41.3 million in the second quarter a year ago. International sales increased 7% to $21.5 million from $20.2 million in the second quarter of 2015. U.S. sales represented 67% of total, sales and international sales represented 33% of total sales during the second quarter.

“Our sales channel development, particularly in the U.S., in combination with contributions from new product launches, is creating revenue growth momentum for Exactech. We continue to build inventory for the revision hip, knee and shoulder systems that are being launched this year. Those products contributed modestly to growth in the first six months. We hope to accelerate that in the second half. We returned to industry leading growth with our Equinoxe shoulder product line and look forward to doing first cases with the Vantage total ankle in the second half of the year. Hip growth momentum is strong as we have gained traction with the Alteon tapered wedge hip stem and Integrip porous metal acetabular component,” Petty said.

Chief Financial Officer Jody Phillips said, “Gross margins increased to 69.3% from 68.6% for the second quarter a year ago, primarily due to the strength in our U.S. Extremity revenues, which carry higher margins. Total operating expenses for the quarter increased 9% to $39.2 million; however, as a percentage of sales, remained at 59% for the second quarter of 2016.  Sales and marketing expenses increased 11% to $23.8 million, most notably due to ongoing investments in the U.S. sales organization.  General and administrative expenses decreased 2% in the second quarter to $5.6 million and research and development expenses increased 16% to $5.3 million during the second quarter.”

Looking forward, Exactech increased its 2016 revenue guidance to $253-$258 million and its diluted EPS target to $1.15–$1.19. For the third quarter ending September 30, 2016, the company anticipates revenues of $58-$60 million and diluted EPS of $0.21-$0.23. The foregoing statements regarding targets for the quarter and full year are forward-looking and actual results may differ materially. These are the company’s targets, not predictions of actual performance.

The financial statements are below.

 Conference Call

The company will hold a conference call with CEO David Petty and key members of the management team on Tuesday, Aug. 2 at 10:00 a.m. EST. The call will cover Exactech’s second quarter 2016 results. Mr. Petty will open the conference call and a question-and-answer session will follow.

To participate in the call, dial 1-888-430-8709 any time after 9:50 a.m. EST on Aug. 2. International and local callers should dial 1-719-325-2361. A live webcast of the call will be available at https://www.hawkassociates.com/profile/exac.cfm or https://public.viavid.com/index.php?id=120383. This call will be archived for approximately 90 days.

About Exactech
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at https://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at https://www.exac.com and https://www.hawkassociates.com.

An investment profile on Exactech may be found at https://www.hawkassociates.com/profile/exac.cfm. To receive future releases in email alerts, sign up at https://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

Non-GAAP financial measures – Because we operate internationally, we present the percentage change in sales by reporting segment on a constant currency basis, which is a non-GAAP financial measure. We calculate this change on a constant currency basis by translating current period sales at the comparable average historical exchange rates for the same period in the prior year. We believe that presenting the percentage change in sales on a constant currency basis assists in the understanding of actual sales fluctuations by excluding the impact of foreign currency fluctuations.

Investor contacts 
Jody Phillips
Executive Vice President of Finance & Chief Financial Officer
352-377-1140

Julie Marshall or Frank Hawkins
Hawk Associates
305-451-1888
E-mail: EXAC@hawkassociates.com

Media contact
Priscilla Bennett
Vice President, Corporate & Marketing Communication
352-377-1140

Menu
X